QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 beam-therapeutics-presents-data-highlighting-robust-manufacturing-process-for-beam-101-at-eha-2024-hybrid-congress-june-13-16-2024

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, toda...

 barclays-maintains-equal-weight-on-beam-therapeutics-lowers-price-target-to-33

Barclays analyst Gena Wang maintains Beam Therapeutics (NASDAQ:BEAM) with a Equal-Weight and lowers the price target from $4...

 wedbush-reiterates-outperform-on-beam-therapeutics-maintains-57-price-target

Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $57 price target.

 popular-crypto-trader-shares-2024-predictions-for-these-three-altcoins

Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam (CRYPTO: BEAM), Arbitr...

 gene-therapy-side-effects-verve-therapeutics-halts-enrollment-of-lead-gene-therapy-trial-in-patients-with-bad-cholesterol

Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regul...

 bmo-capital-maintains-outperform-on-beam-therapeutics-maintains-57-price-target

BMO Capital analyst Kostas Biliouris maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $57 price tar...

 beam-therapeutics-announces-clearance-of-clinical-trial-authorisation-application-for-beam-302-for-the-treatment-of-alpha-1-antitrypsin-deficiency-aatd

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, toda...

 rbc-capital-maintains-sector-perform-on-beam-therapeutics-raises-price-target-to-35

RBC Capital analyst Luca Issi maintains Beam Therapeutics (NASDAQ:BEAM) with a Sector Perform and raises the price target fr...

 why-helix-energy-solutions-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

 norwegian-cruise-line-posts-strong-sales-joins-hims--hers-health-sterling-infrastructure-and-other-big-stocks-moving-higher-on-tuesday

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.

 jp-morgan-upgrades-beam-therapeutics-to-overweight-raises-price-target-to-40

JP Morgan analyst Eric Joseph upgrades Beam Therapeutics (NASDAQ:BEAM) from Neutral to Overweight and raises the price targe...

 bitcoin-ethereum-dogecoin-rise-as-investors-weigh-spot-etf-impact-analyst-says-scenario-for-king-crypto-is-rejection-at-46k-and-then-correction-to-below-40k

Major cryptocurrencies on Tuesday evening posted some gains following a weekend characterized by

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION